Safety Profile of High IgPro20 Infusion Parameters in Patients with Primary Immunodeficiency (PID): Results from The Forced Upward Titration HILO Study

被引：0

作者：

Rojavin, Mikhail ^{[1
]}

Hu, Chengping ^{[2
]}

Anderson, John ^{[3
]}

Bonagura, Vincent ^{[4
]}

Cowan, Juthaporn ^{[5
]}

Lugar, Patricia ^{[6
]}

Maglione, Paul ^{[7
]}

Mustafa, Shahzad ^{[8
,9
]}

Patel, Niraj ^{[10
]}

Routes, John ^{[11
]}

Sriaroon, Panida ^{[12
]}

Vinh, Donald ^{[13
]}

Hofmann, Jutta ^{[1
]}

机构：

[1] CSL Behring, King Of Prussia, PA USA

[2] Allergy & Immunol Specialists PLLC, Glendale, AZ USA

[3] Clin Res Ctr Alabama, Homewood, AL USA

[4] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY USA

[5] Univ Ottawa, Ottawa, ON, Canada

[6] Duke Univ, Med Ctr, Durham, NC 27706 USA

[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[8] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA

[9] Rochester Reg Hlth, Rochester, NY USA

[10] Levine Childrens Hosp, Charlotte, NC USA

[11] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[12] Univ S Florida, Tampa, FL 33620 USA

[13] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

097

引用

页码：AB32 / AB32

页数：1

共 26 条

[21] TOLERABILITY AND SAFETY OF RECOMBINANT HUMAN HYALURONIDASE (RHUPH20)-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNE GLOBULIN (HUMAN), 10% (IGHY) IN PRIMARY IMMUNODEFICIENCY DISEASES: A STUDY FROM NORTH AMERICA
Kobayashi, R.
Darter, A.
Stein, M.
Gupta, S.
Paris, K.
Testori, A.
Engl, W.
Leibl, H.
Fielhauer, K.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 156 - 156
[22] Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study
Rubinstein, Arye
Mabudian, Mohsen
Mcneil, Donald
Patel, Niraj C.
Wasserman, Richard L.
Gupta, Sudhir
Carrasco, Paz
Chen, Jie
Garcia, Enrique
Nagy, Andras
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2024, 44 (08)
[23] Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study
Lebwohl, M. G.
Gordon, K. B.
Gallo, G.
Zhang, L.
Paul, C.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) : 301 - 309
[24] Efficacy, Safety and Tolerability of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results
Stein, Mark R.
Wasserman, Richard L.
Melamed, Isaac
Rubinstein, Arye
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
McCoy, Barbara
Yel, Leman
Schiff, Richard I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 380 - 381
[25] Glofitamab Plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL): results from a Phase Ib study
Topp, M.
Tani, M.
Dickinson, M.
Ghosh, N.
Santoro, A.
Pinto, A.
Bosch, F.
Fox, C. P.
Lopez Guillermo, A.
Carlucci, C.
Wu, C.
Humphrey, K.
Baumlin, P.
Barrett, M.
Qayum, N.
Morschhauser, F.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 207 - 207
[26] Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
Topp, Max S.
Tani, Monica
Dickinson, Michael
Ghosh, Nilanjan
Santoro, Armando
Pinto, Antonio
Bosch, Francesc
Fox, Christopher P.
Lopez-Guillermo, Armando
Carlucci, Claudia
Wu, Chun
Humphrey, Kathryn
Baumlin, Pauline
Barrett, Martin
Qayum, Naseer
Morschhauser, Franck
BLOOD, 2022, 140 : 1775 - 1777

← 1 2 3 →